New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma.

Authors:
Agulnik M.

Journal:
Cancer

Publication Year: 2011

DOI:
10.1002/cncr.26361

PMCID:
PMC3412949

PMID:
21837674

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Cancer

Abbreviation: Cancer

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Tobacco use and cancer-related symptom burden: Analysis of the US Population Assessment of Tobacco …
Price SN; Palmer AM; Fucito LM and 4 more (2023) - Transparency Score: 3/6
A contemporary systematic review on liver transplantation for unresectable liver metastases of colo…
Lebeck Lee CM; Ziogas IA; Agarwal R and 5 more (2022) - Transparency Score: 3/6
Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute mye…
Loke J; Labopin M; Craddock C and 16 more (2022) - Transparency Score: 3/6
Analysis of human leukocyte antigen associations in human papillomavirus-positive and -negative hea…
Ekanayake Weeramange C; Shu D; Tang KD and 10 more (2022) - Transparency Score: 3/6
A proposed global framework for pediatric cancer communication research.
Graetz DE; Caceres-Serrano A; Radhakrishnan V and 3 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICT OF INTEREST DISCLOSURES The author has participated in advisory boards for Novartis Pharmaceuticals and has received honoraria from Novartis Pharmaceuticals."

Evidence found in paper:

"FUNDING SOURCES Editorial support was funded by Merck."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025